搜尋
Chemomab Therapeutics Ltd
CMMB添加自選
1.410USD
+0.050+3.68%
收盤 07-27 16:00（美東）報價延遲15分鐘
40.61M總市值
8.09本益比TTM
關於 Chemomab Therapeutics Ltd 公司
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltd簡介
公司代碼CMMB
公司名稱Chemomab Therapeutics Ltd
上市日期Aug 14, 2012
CEOMor (Adi)
員工數量16
證券類型Depository Receipt
年結日Aug 14
公司地址Kiryat Atidim, Building 7
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編6158002
電話972773310156
網址https://www.chemomab.com/
公司代碼CMMB
上市日期Aug 14, 2012
CEOMor (Adi)
Chemomab Therapeutics Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
常見問題
Chemomab Therapeutics Ltd的前五大股東是誰？
Chemomab Therapeutics Ltd的前五大股東如下：Ms. Sigal Fattal, CPA
有多少機構持有Chemomab Therapeutics Ltd(CMMB)的股份？
截至2026Q1，共有33家機構持有Chemomab Therapeutics Ltd的股份，合計持有的股份價值約為402.96K，占公司總股份的5.60% 。與2025Q4相比，機構持股有所增加，增幅為-450971.00。